Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INMNYSE:NBYNASDAQ:NEPTNASDAQ:PPBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINMInMed Pharmaceuticals$2.53-5.9%$2.78$1.72▼$15.70$3.05M0.171.01 million shs153,795 shsNBYNovaBay Pharmaceuticals$0.60-6.8%$0.57$0.36▼$3.14$3.49M0.43134,617 shs11,123 shsNEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shsPPBTPurple Biotech$2.44-1.0%$2.49$2.00▼$13.95$3.24M0.5270,598 shs4,394 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINMInMed Pharmaceuticals+5.49%-14.87%+2.67%-4.61%-43.79%NBYNovaBay Pharmaceuticals+7.45%+9.14%+9.55%+2.14%-77.73%NEPTNeptune Wellness Solutions0.00%0.00%0.00%0.00%0.00%PPBTPurple Biotech-3.91%-5.75%+9.33%-9.56%+245,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINMInMed Pharmaceuticals1.0239 of 5 stars0.04.00.00.03.60.00.6NBYNovaBay PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/APPBTPurple Biotech2.6685 of 5 stars3.54.00.00.03.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINMInMed Pharmaceuticals 0.00N/AN/AN/ANBYNovaBay Pharmaceuticals 3.00Buy$0.8541.67% UpsideNEPTNeptune Wellness Solutions 0.00N/AN/AN/APPBTPurple Biotech 3.00Buy$33.001,255.24% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINMInMed Pharmaceuticals$4.92M0.62N/AN/A$5.12 per share0.49NBYNovaBay Pharmaceuticals$9.78M0.36N/AN/A$4.25 per share0.14NEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00PPBTPurple BiotechN/AN/AN/AN/A$27.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINMInMed Pharmaceuticals-$7.68M-$12.09N/A∞N/A-163.75%-90.74%-71.70%N/ANBYNovaBay Pharmaceuticals-$9.64M-$53.72N/AN/AN/A-102.72%-7,293.78%-158.41%N/ANEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%N/APPBTPurple Biotech-$19.88M-$2.62N/AN/AN/AN/A-55.86%-44.67%8/15/2025 (Estimated)Latest NEPT, PPBT, NBY, and INM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025PPBTPurple BiotechN/A-$0.17N/A-$0.17N/AN/A5/12/2025Q3 2025INMInMed PharmaceuticalsN/A-$1.94N/A-$1.94N/A$1.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINMInMed PharmaceuticalsN/AN/AN/AN/AN/ANBYNovaBay PharmaceuticalsN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINMInMed Pharmaceuticals0.093.052.44NBYNovaBay PharmaceuticalsN/A1.150.91NEPTNeptune Wellness SolutionsN/A0.230.10PPBTPurple BiotechN/A1.271.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINMInMed Pharmaceuticals20.12%NBYNovaBay Pharmaceuticals23.25%NEPTNeptune Wellness Solutions14.44%PPBTPurple Biotech9.64%Insider OwnershipCompanyInsider OwnershipINMInMed Pharmaceuticals1.43%NBYNovaBay Pharmaceuticals0.10%NEPTNeptune Wellness Solutions5.10%PPBTPurple Biotech2.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINMInMed Pharmaceuticals101.21 million711,000Not OptionableNBYNovaBay Pharmaceuticals305.82 million4.88 millionNot OptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionablePPBTPurple Biotech201.33 million1.29 millionOptionableNEPT, PPBT, NBY, and INM HeadlinesRecent News About These CompaniesPurple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody PlatformJune 4, 2025 | finance.yahoo.comHC Wainwright Predicts Increased Earnings for Purple BiotechJune 3, 2025 | americanbankingnews.comH.C. Wainwright Raises Purple Biotech (PPBT) Price Target, Reiterates Buy RatingJune 1, 2025 | msn.comPurple Biotech Ltd.: Purple Biotech Reports First Quarter 2025 Financial ResultsMay 21, 2025 | finanznachrichten.dePurple Biotech Reports First Quarter 2025 Financial ResultsMay 21, 2025 | globenewswire.comPurple Biotech Appoints Shai Lankry as Chief Financial Officer to Drive Strategic Growth and Financial ExcellenceMay 13, 2025 | nasdaq.comPurple Biotech appoints Shai Lankry as new CFOMay 13, 2025 | investing.comPurple Biotech Ltd.: Purple Biotech Appoints Shai Lankry as Chief Financial OfficerMay 12, 2025 | finanznachrichten.dePurple Biotech Appoints Shai Lankry as Chief Financial OfficerMay 12, 2025 | globenewswire.comPurple Biotech Unveils Promising Phase 2 Results for CM24 in Pancreatic CancerApril 30, 2025 | tipranks.comPurple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck CancersApril 28, 2025 | globenewswire.comPurple Biotech announces publication of study on potential of NT219April 17, 2025 | markets.businessinsider.comPurple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research MeetingMarch 28, 2025 | finance.yahoo.comPurple Biotech Unveils Updated Oncology Pipeline ProgressMarch 18, 2025 | tipranks.comPurple Biotech Reports Positive Clinical Trial Results for CM24 and NT219, Advancing to Phase 2 StudiesMarch 12, 2025 | nasdaq.comPurple Biotech reports Q4 EPS (26c) vs. ($3.80) last yearMarch 10, 2025 | markets.businessinsider.comPurple Biotech sees cash runway into mid-2026March 10, 2025 | markets.businessinsider.comPurple Biotech Reports Fourth Quarter and Full-Year 2024 Financial ResultsMarch 10, 2025 | globenewswire.comPurple Biotech granted new U.S. patent for NT219March 5, 2025 | markets.businessinsider.comPurple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major MarketsMarch 5, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNEPT, PPBT, NBY, and INM Company DescriptionsInMed Pharmaceuticals NASDAQ:INM$2.53 -0.16 (-5.95%) Closing price 04:00 PM EasternExtended Trading$2.58 +0.05 (+1.78%) As of 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.NovaBay Pharmaceuticals NYSE:NBY$0.60 -0.04 (-6.77%) As of 03:57 PM EasternNovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Neptune Wellness Solutions NASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. Purple Biotech NASDAQ:PPBT$2.44 -0.03 (-1.02%) As of 03:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
